Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
08 December 2021 | Story Michelle Nothling | Photo Supplied
Lentsu Nchabeleng
Dr Ntheno Nchabeleng was appointed as the Deputy Director in the Gender and Anti-Discrimination Office within the Unit for Institutional Change and Social Justice.

A total of 10 006 rape cases were reported between April and June 2021. This is according to the latest SA crime statistics for the first quarter of 2021/2022. From a sample of 5 439 of these rape cases, 3 766 of incidents took place in the victim’s home or that of the rapist. A shadow pandemic of gender-based violence against our women and children is raging in South Africa.

It is within this global and local context that the Gender and Anti-Discrimination Office (GEADO) at the university is making inroads into supporting survivors of gender-based violence (GBV) and changing gender stereotypes.

GEADO in focus

GEADO is situated within the Unit for Institutional Change and Social Justice on the Bloemfontein Campus. It is mandated to deal with incidents of unfair discrimination and GBV as it relates to the UFS community, and to conduct advocacy and training in these areas. Deputy Director of GEADO, Dr Ntheno Nchabeleng, explains that “through high-impact practices and interventions, the Office works to systematically reduce case attrition to ensure that all reports and cases follow procedurally just processes”.

GEADO has been established at all the UFS campuses with well-trained and fully equipped Senior Gender Officers leading each. Geraldine Langau—supported by research assistant Delisile Mngadi—is managing the office at the Bloemfontein Campus, Chelepe Mocwana the Qwaqwa Campus, and Sivuyisiwe Magayana oversees the South Campus office.

Addressing gender-based violence

Prevention and response to GBV are at the core of GEADO’s work. With our country wracked by sexual violence and femicide, “it has become a nightmare to be a woman in South Africa”, Dr Nchabeleng says.

Its preventative efforts focus on the underlying causes of GBV to transform patriarchal notions, misogynistic norms, power imbalances, and toxic gender stereotypes. Fostering collaboration with various strategic partners to strengthen its impact, GEADO recently started working with Amnesty International Sub-Saharan Africa and Amnesty International Latin America to spread awareness on various forms of violence experienced by vulnerable populations. GEADO has also partnered with other local stakeholders in an effort to eradicate GBV through programming that includes awareness campaigns, online mobilisation, training, and webinars.

Becoming part of the solution

“Become change agents,” Dr Nchabeleng urges. One way to start shifting attitudes and mindsets is to change the way we speak. Examples would be to refrain from sexist and discriminatory language and phrases that undermine and degrade our women. Gendered name-calling generally depicts women and girls as inferior and less than fully human. Another area of concern is the way young people — especially young men — engage in disparaging conversations about women on social media platforms. This behaviour needs to cease. As a society, we also need to stop victim blaming, stop normalising rape culture, and stop entertaining sexual violence jokes,” Dr Nchabeleng says.

These changes start with each of us.

Incidents of GBV and discrimination can be reported to GEADO at:
Bloemfontein Campus: +27 51 401 3982
South Campus: +27 51 401 7544
Qwaqwa Campus: +27 58 718 5431

Sexual Assault Response Team (SART):
www.ufs.ac.za/sart 
Toll-free number +27 80 020 4682

News Archive

HIV Cure – Just another fantasy?
2016-07-27

Description: HIV Cure – Just another fantasy? Tags: HIV Cure – Just another fantasy?

Dr Dominique Goedhals, Prof John Frater,
Dr Thabiso Mofokeng and Dr Jacob Jansen van Vuuren,
attended the lecture. Prof Frater has been working in
collaboration with the UFS Department of Internal
Medicine on HIV resistance and HIV immunology
since 2007.

Photo: Nonsindiso Qwabe

Twenty-years ago, after a person had been diagnosed with HIV, their lifespan did not exceed three years, but thanks to the success of antiretroviral therapy programmes, life expectancy has risen by an average of ten years. However, is antiretroviral therapy always going to be for life? This is the societal issue that Professor John Frater, addressed in his talk at the University of the Free State. He is an MRC Senior Clinical Fellow, Associate Professor and Honorary Consultant Physician in Infectious Diseases at  Oxford University.

Antiretroviral medicine therapeutic

The discovery of antiretroviral therapy - the use of HIV medicines to treat the virus - has had a positive effect on the health and well-being of people living with it, improving their quality of life. Unfortunately, if treatment is stopped, HIV rebounds to the detriment of the patient. Now, research has shown that some patients, who are treated soon after being infected by HIV, may go off treatment for prolonged periods. Work is being done to predict who will be able to stop treatment.

“The difference made by starting treatment earlier is enormous. Delaying treatment is denying yourself the right to health,” Professor Frater says. However, this does not mean that the virus is cured. “A person can live for ten years without being on HIV treatment, but is that enough?” he went on to ask.

Healthy lifestyles encouraged

The National Department of Health will adopt a test and treat immediately strategy later this year to improve patient health and curb the spread of HIV. ,This is another reason why everybody should know their status and start treatment as soon as possible.

Search for a cure continues

More research is being conducted to establish whether HIV can be eradicated. Remission gives hope that a permanent cure may be found eventually. “Will a cure for HIV ever be found? Time will tell,” he concluded.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept